Skip to main content
SpringerLink
Log in

Stem Cell Donation

Availability of unrelated donors for hematopoietic stem cell transplantation for hemoglobinopathies

  • Original Article
  • Published:
Bone Marrow Transplantation Submit manuscript

Summary:

Hematopoietic stem cell transplantation (HSCT) is the only curative option for patients with hemoglobinopathies. However, fewer than 30% of individuals will have an HLA-identical sibling. Improvement in outcomes after HSCT using unrelated donors (URD), and the development of novel nontoxic preparative regimens may make URD HSCT an option for hemoglobinopathy patients who do not have an HLA-identical sibling donor. The National Marrow Donor Program® (NMDP) maintains a Registry of 4 million volunteer donors, and facilitates URD HSCT for patients with life-threatening blood diseases. In light of the increased representation of minorities in the NMDP registry, donor searches were run in April 2001 for a cohort of 272 thalassemia patients and 77 sickle cell disease (SCD) patients for whom searches had been submitted between 1989 and 2001 in order to determine the current likelihood of finding a potential donor of hematopoietic stem cells for hemoglobinopathy patients. About 59.7% SCD patients 80.2% thalassemia patients will find at least one potential 6/6 HLA matched donor or umbilical cord blood (UCB) unit. All patients will find at least one donor or UCB that is a potential 5/6 HLA match. In conclusion the majority of hemoglobinopathy patients will find at least one potential HLA matched unrelated bone marrow donor or UCB.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Figure 1

Similar content being viewed by others

References

  1. Walters MC, Storb R, Patience M et al. Impact of bone marrow transplantation for symptomatic sickle cell disease: an interim report. Multicenter investigation of bone marrow transplantation for sickle cell disease. Blood 2000; 95: 1918–1924.

    CAS  PubMed  Google Scholar 

  2. Lucarelli G, Galimberti M, Giardini C et al. Bone marrow transplantation in thalassemia. The experience of Pesaro. Ann NY Acad Sci 1998; 850: 270–275.

    Article  CAS  Google Scholar 

  3. Walters MC, Patience M, Leisenring W et al. Barriers to bone marrow transplantation for sickle cell anemia. Biol Blood Marrow Transplant 1996; 2: 100–104.

    CAS  Google Scholar 

  4. Gaziev D, Galimberti M, Lucarelli G et al. Bone marrow transplantation from alternative donors for thalassemia: HLA-phenotypically identical relative and HLA-nonidentical sibling or parent transplants. Bone Marrow Transplant 2000; 25: 815–821.

    Article  CAS  Google Scholar 

  5. La Nasa G, Giardini C, Argiolu F et al. Unrelated donor bone marrow transplantation for thalassemia: the effect of extended haplotypes. Blood 2002; 99: 4350–4356.

    Article  CAS  Google Scholar 

  6. Crespo Chozas D, Maldonado Regalado MS, Munoz Villa A . Unrelated donor bone marrow transplantation in a girl with thalassemia major. Med Clin (Barc) 2000; 114: 598–599.

    Article  CAS  Google Scholar 

  7. Contu L, La Nasa G, Arras M et al. Successful unrelated bone marrow transplantation in beta-thalassaemia. Bone Marrow Transplant 1994; 13: 329–331.

    CAS  PubMed  Google Scholar 

  8. Cheng CN, Lu CC, Sun HF et al. Successful matched-unrelated bone marrow transplantation in a patient with Beta-thalassemia major. J Pediatr Hematol Oncol 2002; 24: 579–581.

    Article  Google Scholar 

  9. Golden F . The sickle-cell kid. An experimental transplant succeeds, giving a brave little boy the best Christmas present he can imagine. Time 1999; 154: 92.

    CAS  PubMed  Google Scholar 

  10. Sullivan KM, Anasetti C, Horowitz M et al. Unrelated and HLA-nonidentical related donor marrow transplantation for thalassemia and leukemia. A combined report from the Seattle Marrow Transplant Team and the International Bone Marrow Transplant Registry. Ann NY Acad Sci 1998; 850: 312–324.

    Article  CAS  Google Scholar 

  11. Maiers M, Flesch S . Unrelated Donor Hematopoetic Stem Cell Transplantation for Hemoglobinopathies Facilitated by NMDP. National Marrow Donor Program: Minneapolis; 2002.

    Google Scholar 

  12. Krishnamurti L, Blazar BR, Wagner JE . Bone marrow transplantation without myeloablation for sickle cell disease. N Engl J Med 2001; 344: 68.

    Article  CAS  Google Scholar 

  13. Schleuning M, Stoetzer O, Waterhouse C et al. Hematopoietic stem cell transplantation after reduced-intensity conditioning as treatment of sickle cell disease. Exp Hematol 2002; 30: 7–10.

    Article  Google Scholar 

  14. Chakraverty R, Peggs K, Chopra R et al. Limiting transplantation-related mortality following unrelated donor stem cell transplantation by using a nonmyeloablative conditioning regimen. Blood 2002; 99: 1071–1078.

    Article  CAS  Google Scholar 

  15. Anasetti C, Petersdorf EW, Martin PJ et al. Improving availability and safety of unrelated donor transplants. Curr Opin Oncol 2000; 12: 121–126.

    Article  CAS  Google Scholar 

  16. Gutoski M . Study verifies lack of ethnic diversity in bone marrow donors. Oncol Nurs Forum. 1995; 22: 717.

    CAS  PubMed  Google Scholar 

  17. Freytes CO, Beatty PG . Representation of Hispanics in the National Marrow Donor Program. Bone Marrow Transplant 1996; 17: 323–327.

    CAS  PubMed  Google Scholar 

  18. Yancey AK, Coppo P, Kawanishi Y . Progress in availability of donors of color: the National Marrow Donor Program. Transplant Proc 1997; 29: 3760–3765.

    Article  CAS  Google Scholar 

  19. Antin JH, Childs R, Filipovich AH et al. Establishment of complete and mixed donor chimerism after allogeneic lymphohematopoietic transplantation: recommendations from a workshop at the 2001 tandem meetings. Biol Blood Marrow Transplant 2001; 7: 473–485.

    Article  CAS  Google Scholar 

  20. Davies SM, DeFor TE, McGlave PB et al. Equivalent outcomes in patients with chronic myelogenous leukemia after early transplantation of phenotypically matched bone marrow from related or unrelated donors. Am J Med 2001; 110: 339–346.

    Article  CAS  Google Scholar 

  21. Mentzer WC . Bone marrow transplantation for hemoglobinopathies. Curr Opin Hematol 2000; 7: 95–100.

    Article  CAS  Google Scholar 

  22. Confer DL . The National Marrow Donor Program. Meeting the needs of the medically underserved. Cancer 2001; 91: 274–278.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Hematology/Oncology/Blood and Marrow Transplantation, Children's Hospital of Pittsburgh, Pittsburgh, PA, USA

    L Krishnamurti

  2. Division of Pediatric Hematology/Oncology/Blood and Marrow Transplantation, University of Minnesota, Minneapolis, MN, USA

    S Abel

  3. National Marrow Donor Program, Minneapolis, MN, USA

    M Maiers & S Flesch

Authors
  1. L Krishnamurti
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. S Abel
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. M Maiers
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. S Flesch
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Krishnamurti, L., Abel, S., Maiers, M. et al. Availability of unrelated donors for hematopoietic stem cell transplantation for hemoglobinopathies. Bone Marrow Transplant 31, 547–550 (2003). https://doi.org/10.1038/sj.bmt.1703887

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.bmt.1703887

  • Springer Nature Limited

Keywords

This article is cited by

Search

Navigation